- Home
- ACRV vs MAIA Comparison
ACRV vs MAIA Comparison
Compare ACRV & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- MAIA
- Stock Information
- Founded
- ACRV 2018
- MAIA 2018
- Country
- ACRV United States
- MAIA United States
- Employees
- ACRV N/A
- MAIA N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- MAIA Health Care
- Exchange
- ACRV Nasdaq
- MAIA Nasdaq
- Market Cap
- ACRV 42.5M
- MAIA 44.8M
- IPO Year
- ACRV 2022
- MAIA 2022
- Fundamental
- Price
- ACRV $1.81
- MAIA $1.55
- Analyst Decision
- ACRV Strong Buy
- MAIA
- Analyst Count
- ACRV 6
- MAIA 0
- Target Price
- ACRV $21.80
- MAIA N/A
- AVG Volume (30 Days)
- ACRV 412.6K
- MAIA 75.2K
- Earning Date
- ACRV 05-13-2025
- MAIA 05-13-2025
- Dividend Yield
- ACRV N/A
- MAIA N/A
- EPS Growth
- ACRV N/A
- MAIA N/A
- EPS
- ACRV N/A
- MAIA N/A
- Revenue
- ACRV N/A
- MAIA N/A
- Revenue This Year
- ACRV N/A
- MAIA N/A
- Revenue Next Year
- ACRV N/A
- MAIA N/A
- P/E Ratio
- ACRV N/A
- MAIA N/A
- Revenue Growth
- ACRV N/A
- MAIA N/A
- 52 Week Low
- ACRV $1.30
- MAIA $1.40
- 52 Week High
- ACRV $11.51
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- ACRV 34.69
- MAIA 46.60
- Support Level
- ACRV $1.30
- MAIA $1.41
- Resistance Level
- ACRV $2.19
- MAIA $1.61
- Average True Range (ATR)
- ACRV 0.32
- MAIA 0.11
- MACD
- ACRV 0.10
- MAIA 0.01
- Stochastic Oscillator
- ACRV 51.00
- MAIA 62.50
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.